In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats.
A strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose, is observed.
A study in normal rats also confirmed that SBM-TFC-039 triggered elimination of glucose through the urine (glycosuria) in a dose dependent manner.
SBM-TFC-039 also reduced blood glucose excursions following a glucose challenge by 34 percent compared to an untreated group, the company said.